Everything below concerns lyophilized powder. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-05-23. Numbers and descriptions here follow the published literature rather than marketing material.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
Interpretation depends on study phase and duration. Phase 2 programs are powered for weight and safety signals, not for cardiovascular or renal outcomes, which require event-driven designs. Gastrointestinal events such as nausea, diarrhea, vomiting, and constipation are the most frequently reported adverse effects and tend to cluster around dose escalation. Small increases in heart rate have been described. Because follow-up after treatment discontinuation is limited, questions about weight regain and durability are open rather than answered.
Trial reports for this compound rely on a small set of repeated measures. Body weight is normally expressed as percent change from baseline at a fixed week, with absolute kilograms given secondarily. Glycemic endpoints include HbA1c, fasting glucose, and, in some protocols, continuous glucose monitoring summaries. Imaging endpoints such as MRI-derived proton density fat fraction quantify liver fat. Standardization matters because a percent change and a categorical responder analysis can tell different stories about the same dataset.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Studied for metabolic indications |
| Receptor activity | GIP, GLP-1, and glucagon | Single molecule, three targets |
| Development status | Investigational | Not an approved therapy |
| Common synonym | LY3437943 | Development designation |
| Administration route | Subcutaneous injection | As used in clinical studies |
Retatrutide is an investigational peptide studied for obesity and type 2 diabetes. It is a single synthetic molecule designed to activate three metabolic receptors simultaneously. The compound belongs to the incretin mimetic family, a group of peptides that imitate gut hormones involved in appetite and glucose control. Its research code is LY3437943, and it remains under clinical study rather than cleared for routine medical use.
Acting as a triple agonist, the molecule binds the GLP-1, GIP, and glucagon receptors. GLP-1 activity slows gastric emptying and dampens appetite, while GIP signaling contributes to insulin sensitivity and fat metabolism. Glucagon receptor engagement raises energy expenditure and encourages fat breakdown, although it can also elevate blood glucose. Combining three pathways is intended to yield larger weight reduction than single or dual agonists, and researchers continue to examine how the balance among them shapes tolerability.
Clinical studies have reported notable reductions in body weight among participants. Early trials measured safety and explored several dose levels, and later studies tracked body-weight change over months of treatment. Investigators also monitor effects on glycemic markers, liver fat, and blood lipids. Because the compound is still in development, questions about long-term safety, cardiovascular outcomes, and durability after treatment ends remain open.
Dissolution behavior depends on the amino acid sequence, the counterion content, and the buffer chosen. Many peptides disperse readily in water or mild aqueous buffers, while others require a small amount of organic co-solvent or a change in pH. Adsorption to plastic and glass surfaces can reduce the concentration of a solution over time, particularly at low concentrations. Filtration before analysis removes particulates, and aliquoting limits repeated freeze-thaw cycles that stress the material.
Research-grade peptide material is commonly supplied as a lyophilized powder, a form that limits degradation during transport and storage. Standard practice keeps such material cold and protected from light and moisture, with tighter conditions used for long-term archives. Once dissolved, solutions are generally considered less stable than the dry powder and are handled on shorter timescales. These established conventions derive largely from general peptide chemistry rather than from compound-specific evidence alone.
=== Official demolition === On 13 June 1990, the East German Border Troops officially began dismantling the Wall, beginning in Bernauer Straße and around the Mitte district. From there, demolition continued through Prenzlauer Berg/Gesundbrunnen, Heiligensee and throughout the city of Berlin until December 1990. According to estimates by the border troops, a total of around 1.7 million tonnes of building rubble was produced by the demolition. Unofficially, the demolition of the Bornholmer Straße crossing began because of construction work on the railway. This involved a total of 300 GDR border guards and—after 3 October 1990—600 Pioneers of the Bundeswehr. These were equipped with 175 trucks, 65 cranes, 55 excavators and 13 bulldozers. Virtually every road that was severed by the Berlin Wall, every road that once linked from West Berlin to East Berlin, was reconstructed and reopened by 1 August 1990. In Berlin alone, 184 km (114 mi) of wall, 154 km (96 mi) border fence, 144 km (89 mi) signal systems and 87 km (54 mi) barrier ditches were removed. What remained were six sections that were to be preserved as a memorial. Various military units dismantled the Berlin/Brandenburg border wall, completing the job in November 1991. Painted wall segments with artistically valuable motifs were put up for auction in 1990 in Berlin and Monte Carlo. On 1 July 1990, the day East Germany adopted the West German currency, all de jure border controls ceased, although the inter-German border had become meaningless for some time before that. The demolition of the Wall was completed in 1994.
Another area of Berman's research concerns antifungal drug resistance and tolerance. Her collaborative studies have examined how fungal cells adapt to antifungal drugs through genetic and physiological changes, including the association between aneuploidy and drug resistance in C. albicans. This work has included research on the formation of isochromosomes that increase the copy number of genes involved in drug responses, as well as how adaptation to one drug can alter responses to other drugs. Berman has distinguished antifungal tolerance from resistance by examining variations in drug responses among individual cells within a population. This research has explored the association between tolerance and persistent Candida bloodstream infections, together with the effects of metabolism and interactions among microorganisms on drug responses. She has also studied drug responses in Candida glabrata, Candida auris and Cryptococcus neoformans, as well as combinations of antifungal drugs. At Tel Aviv University, Berman's research received support through a European Research Council Advanced Grant for the RAPLODAPT project, covering 2014–2018, and a Synergy Grant for the FungalTolerance project, covering 2021–2027. The latter project, a collaboration with Markus Ralser and his team at Charité's Institute of Biochemistry, investigates the mechanisms by which invasive fungal pathogens survive exposure to antifungal drugs across multiple levels of biological organization.
=== Ionization-type smoke detector === Americium-241 is the only synthetic isotope to have found its way into the household, where the most common type of smoke detector (the ionization type) uses 241AmO2 (americium-241 dioxide) as a source of ionizing radiation. This isotope is preferred over 226Ra because it emits 5 times more alpha particles and relatively little harmful gamma radiation. With its half-life of 432.6 years, the americium in a smoke detector decreases and includes about 3% neptunium after 19 years, and about 5% after 32 years. The amount of americium in a typical new smoke detector is 0.29 micrograms (4.5×10−6 grains) (about 1/3000 the weight of a small grain of sand) with an activity of 1 microcurie (37 kBq). Some old industrial smoke detectors (notably from the Pyrotronics Corporation) can contain up to 80 microcuries (3,000 kBq). The amount of 241Am declines slowly as it decays into neptunium-237 (237Np), a different transuranic element with a much longer half-life (2.144 million years). The radiated alpha particles pass through an ionization chamber, an air-filled space between two electrodes, which allows a small, constant electric current to pass between the capacitor plates due to the radiation ionizing the air space between. Any smoke that enters the chamber blocks/absorbs some of the alpha particles from freely passing through and reduces the ionization and therefore causes a drop in the current. The alarm's circuitry detects this drop in the current and as a result, triggers the piezoelectric buzzer to sound.
=== Pharmacodynamics === Aticaprant is a potent, selective, short-acting (i.e., non-"inactivating") antagonist of the KOR (Ki = 0.81 nM vs. 24.0 nM and 155 nM for the μ-opioid receptor (MOR) and δ-opioid receptor (DOR), respectively; approximately 30-fold selectivity for the KOR). The drug has been found to dose-dependently block fentanyl-induced miosis at 25 mg and 60 mg in humans (with minimal to no blockade at doses of 4 to 10 mg), suggesting that the drug significantly occupies and antagonizes the MOR at a dose of at least 25 mg but not of 10 mg or less. However, a more recent study assessing neuroendocrine effects of the drug in normal volunteers and subjects with a history of cocaine dependence reported observations consistent with modest MOR antagonism at the 10 mg dose. In animal models of depression, aticaprant has been found to have potent synergistic efficacy in combination with other antidepressants such as citalopram and imipramine. Positron emission tomography imaging revealed that brain KORs were almost completely saturated by the drug 2.5 hours following a single dose of 10 mg, which supported the 4 mg to 25 mg dosages that aticaprant is being explored at in clinical trials. Occupancy was 35% for a 0.5 mg dose and 94% for a 10 mg dose. At 24 hours post-dose, receptor occupancy was 19% for 0.5 mg and 82% for 25 mg. No serious side effects were observed, and all side effects seen were mild to moderate and were not thought to be due to aticaprant.
=== Modern documentaries === Box office analysts have noted that the documentary film genre has become increasingly successful in theatrical release with films such as Fahrenheit 9/11, Super Size Me, Food, Inc., Earth, March of the Penguins, and An Inconvenient Truth among the most prominent examples. Compared to dramatic narrative films, documentaries typically have far lower budgets which makes them attractive to film companies because even a limited theatrical release can be highly profitable. The nature of documentary films has expanded over the past 30 years from the cinéma vérité style introduced in the 1960s in which portable camera and sound equipment allowed an intimate relationship between filmmaker and subject. The line blurs between documentary and narrative and some works are very personal, such as Marlon Riggs's Tongues Untied (1989) and Black Is...Black Ain't (1995), which mix expressive, poetic, and rhetorical elements and stress subjectivities rather than historical materials. Historical documentaries, such as the landmark 14-hour Eyes on the Prize: America's Civil Rights Years (1986 – Part 1 and 1989 – Part 2) by Henry Hampton, 4 Little Girls (1997) by Spike Lee, The Civil War by Ken Burns, and UNESCO-awarded independent film on slavery 500 Years Later, express not only a distinctive voice but also a perspective and point of views. Some films such as The Thin Blue Line by Errol Morris incorporate stylized re-enactments, and Michael Moore's Roger & Me place far more interpretive control with the director.
Sources: en.wikipedia.org
Glucose concentrations in the atmosphere are detected via collection of samples by aircraft and are known to vary from location to location. For example, glucose concentrations in atmospheric air ranges from 0.8 to 20.1 pg/L in inland China, to 10.3 to 142 pg/L in East coastal China.
=== Intrauterine administration === A one-year progesterone intrauterine device (IUD) for hormonal birth control was previously available in the United States and a few other countries under the brand name Progestasert. It was marketed between 1976 and 2001. The IUD was never widely used due to a relatively high contraceptive failure rate of 2.9% and the requirement of annual replacement. It contained 38 mg progesterone and released 65 μg progesterone into the uterus per day (totaling up to about 35 mg after one year). For comparison, a woman's body produces on average about 25 mg progesterone per day during the luteal phase. While effective as a form of contraception and for decreasing menstrual bleeding and discomfort, long-lived IUDs can fundamentally only deliver small amounts of progesterone per day, and hence intrauterine progesterone cannot achieve adequate circulating progesterone levels and is unsuitable as a form of systemic therapy. Aside from progesterone, IUDs of progestins, such as levonorgestrel (Mirena/Levosert/Skyla), are available as well.
In the second reaction, an α-amino acid, or an ester of it, is reduced by sodium amalgam and ethanolic HCl to give an α-amino aldehyde. This process is conceptually similar to the Bouveault–Blanc reduction except that it stops at the aldehyde stage rather than reducing the ester all the way to two alcohols.
Mestanolone, also known as 17α-methyl-4,5α-dihydrotestosterone (17α-methyl-DHT) or as 17α-methyl-5α-androstan-17β-ol-3-one, is a synthetic androstane steroid and a 17α-alkylated derivative of dihydrotestosterone (DHT). It differs from DHT only by the presence of the methyl group at the C17α position. Close synthetic relatives of mestanolone include oxandrolone (2-oxa-17α-methyl-DHT), oxymetholone (2-hydroxymethylene-17α-methyl-DHT), and stanozolol (a derivative of 17α-methyl-DHT (mestanolone) with a pyrazole ring fused to the A ring).
Sources: en.wikipedia.org
Glucose is converted into glucose 6-phosphate by the action of glucokinase or hexokinase with conversion of ATP to ADP. Glucose-6-phosphate is converted into glucose-1-phosphate by the action of phosphoglucomutase, passing through the obligatory intermediate glucose-1,6-bisphosphate. Glucose-1-phosphate is converted into UDP-glucose by the action of the enzyme UDP-glucose pyrophosphorylase. Pyrophosphate is formed, which is later hydrolysed by pyrophosphatase into two phosphate molecules. The enzyme glycogenin is needed to create initial short glycogen chains, which are then lengthened and branched by the other enzymes of glycogenesis. Glycogenin, a homodimer, has a tyrosine residue on each subunit that serves as the anchor for the reducing end of glycogen. Initially, about seven UDP-glucose molecules are added to each tyrosine residue by glycogenin, forming α(1→4) bonds. Once a chain of seven glucose monomers is formed, glycogen synthase binds to the growing glycogen chain and adds UDP-glucose to the 4-hydroxyl group of the glucosyl residue on the non-reducing end of the glycogen chain, forming more α(1→4) bonds in the process. Branches are made by glycogen branching enzyme (also known as amylo-α(1:4)→α(1:6)transglycosylase), which transfers the end of the chain onto an earlier part via α-1:6 glycosidic bond, forming branches, which further grow by addition of more α-1:4 glycosidic units.
In Canada, cream soda is mostly pink with a taste reminiscent of grenadine, although clear versions can be found in Quebec and Atlantic Canada. Some brands, such as Fanta, market clear cream soda nationwide. Many brands have a long-lasting, foamy head. Brands include:
=== Division of Animal Nutrition === In March 1927, due to the concerted efforts of Professor David Rivett, and following an agreement with the University of Adelaide that Robertson could continue his relationship with the university, Robertson became the head of the CSIR's first-ever division, the Division of Animal Nutrition. A red brick two-storey building, funded by the Commonwealth Government, and dedicated to animal nutrition research, was designed by the university's architect, Louis Laybourne-Smith. It contained a special laboratory designed by Robertson, and was erected by the CSIR on the university's campus "upon land very generously made available for this purpose by the University" (BR.65). The CSIR Building, known today as The Brailsford Robertson Building, was opened by the Prime Minister, Stanley Bruce, on 22 October 1928.
From the beginning of the Gaza war, reports emerged of children being killed and maimed. Children were also killed in Israeli airstrikes, including in areas designated as “safe zones” by the IDF. The numbers rose rapidly. During the first week of the war in October 2023, at least 447 children were killed. By 3 December 2023, the number had reached an estimated 6,150 children, rising to about an estimated 10,000 by mid-January 2024, with thousands more believed to be buried under rubble. Defense for Children International put the figure at 12,100 children in early February, and mid-April 2024 estimates cited around 14,500 fatalities. In May 2024, the United Nations adjusted its estimate down from 14,500 children to 7,797 identified child deaths, and by December 2024, the overall figure was again reported at roughly 14,500. By 3 September 2025, at least 19,424 children had been reported killed. In March 2024, the United Nations stated that more children had died in Gaza between October 2023 and February 2024 than the sum of all global conflicts from 2019 to 2022. Catherine M. Russell, the head of UNICEF, stated, "We haven’t seen that rate of death among children in almost any other conflict in the world". In late September 2024, Oxfam and Action on Armed Violence reported that the number of children killed in Gaza over the past year was the highest recorded in a single year for any conflict worldwide in the last 20 years.
Red blood cells of non-mammalian vertebrates are flattened and ovoid in form, and retain their cell nuclei. There is considerable variation in the types and proportions of white blood cells; for example, acidophils are generally more common than in humans. Platelets are unique to mammals; in other vertebrates, small nucleated, spindle cells called thrombocytes are responsible for blood clotting instead.
Sources: en.wikipedia.org
It is described as a single molecule that acts at three receptors: the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This triple activity distinguishes it from agents that target one or two of these pathways.
It is characterized in the literature as an investigational agent under clinical study. Approval status depends on jurisdiction, and readers should check current regulatory information rather than assume availability.
The combination is intended to pair appetite-related and glucose-related effects with mechanisms that increase energy expenditure. Whether the combined profile offers advantages over simpler agonists is the subject of ongoing research.
A responder analysis counts participants who cross a threshold, such as five or ten percent weight loss. It complements average percent change by showing how widely results are distributed. The two measures can diverge when a subset of participants loses a large amount.